Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells
Blood · 06.04.2023 · 141 (14) · 1718-1723
DOI: 10.1182/blood.2022017795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 06.04.2023. Verfasst von Joseph C Rimando und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antibodies, Bispecific, Antineoplastic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) relapse is one of the most common and significant adverse events following allogeneic hematopoietic cell transplantation (HCT). Downregulation of major histocompatibility class II (MHC-II) surface expression on AML blasts may represent a mechanism of escape from the graft-versus-malignancy effect and facilitate relapse. We hypothesized that T-cell immunotherapies targeting AML antigens would upregulate MHC-II surface expression via localized release of interferon gamma (IFN-γ), a protein known to upregulate MHC-II expression via JAK-STAT signaling. We demonstrate that flotetuzumab (FLZ), a CD123 × CD3 bispecific DART molecule, and chimeric antigen receptor expressing T cells targeting CD123, CD33, or CD371 upregulate MHC-II surface expression in vitro on a THP-1 AML cell line with intermediate MHC-II expression and 4 primary AML samples from patients relapsing after HCT with low MHC-II expression. We additionally show that FLZ upregulates MHC-II expression in a patient-derived xenograft model and in patients with relapsed or refractory AML who were treated with FLZ in a clinical trial. Finally, we report that FLZ-induced MHC-II upregulation is mediated by IFN-γ. In conclusion, we provide evidence that T-cell immunotherapies targeting relapsed AML can kill AML via both MHC-independent mechanisms and by an MHC-dependent mechanism through local release of IFN-γ and subsequent upregulation of MHC-II expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
- MacroGenics, Inc, Rockville, MD.
ORCID-Profile: Reyka Jayasinghe
Förderung
- NCI NIH HHS
Zitieren
APA
Rimando, J. C., Chendamarai, E., Rettig, M. P., Jayasinghe, R., Christopher, M. J., Ritchey, J. K., Christ, S., Kim, M. Y., Bonvini, E., & DiPersio, J. F. (2023). Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells. Blood, 141(14), 1718-1723. https://doi.org/10.1182/blood.2022017795
Vancouver
Rimando JC, Chendamarai E, Rettig MP, Jayasinghe R, Christopher MJ, Ritchey JK, et al. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells. Blood. 2023;141(14):1718-1723. doi:10.1182/blood.2022017795
BibTeX
@article{Rimando2023,
author = {Rimando, Joseph C and Chendamarai, Ezhilarasi and Rettig, Michael P and Jayasinghe, Reyka and Christopher, Matthew J and Ritchey, Julie K and Christ, Stephanie and Kim, Miriam Y and Bonvini, Ezio and DiPersio, John F},
title = {Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells},
journal = {Blood},
year = {2023},
volume = {141},
number = {14},
pages = {1718--1723},
doi = {10.1182/blood.2022017795}
}
EUVIMED